BioSpace News Archive

Ocean Biomedical and Aesther Healthcare Acquisition Corp. announced the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022.

SPR Therapeutics announced the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System.

Medical robotics innovator Noah Medical revealed the next physician-only review and evaluation of the Galaxy System will take place from October 16-19, 2022 at the The American College of Chest Physicians annual meeting in Nashville, TN.

Impel Pharmaceuticals Inc. announced that the Company will participate in two upcoming investor conferences in September.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at two upcoming investor conferences.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco (AIFA), has enabled reimbursed access to Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC) patients in Italy.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

Protalix BioTherapeutics, Inc. announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference.

Viatris Inc., a global pharmaceutical company, announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022.